Advances in CRISPR-Cas systems for kidney diseases

Area of Science:

• Genetics and Molecular Biology
• Nephrology
• Biotechnology

Background:

• Kidney diseases encompass a range of conditions including acute kidney injury (AKI), chronic kidney disease (CKD), diabetic kidney disease (DKD), lupus nephritis (LN), and polycystic kidney disease (PKD).
• Current treatments often manage symptoms rather than addressing underlying genetic causes.
• CRISPR-Cas technology has emerged as a powerful tool for genetic manipulation.

Purpose of the Study:

• To review recent advancements in CRISPR-Cas systems for kidney disease research and treatment.
• To explore the potential of CRISPR-Cas technology in addressing both monogenic and complex kidney disorders.
• To highlight the versatility of CRISPR-Cas in targeting DNA and noncoding RNA in kidney diseases.

Main Methods:

• Review of recent scientific literature on CRISPR-Cas applications in nephrology.
• Analysis of CRISPR-Cas technology's potential for genetic editing in various kidney disease models.
• Examination of CRISPR-Cas capabilities beyond DNA editing, including noncoding RNA modification.

Main Results:

• CRISPR-Cas technology enables precise genetic modification for monogenic kidney disorders like PKD and Alport syndrome.
• CRISPR-Cas shows promise for treating AKI, CKD, and DKD by editing causative mutations.
• The technology can be adapted for tailored therapies and editing noncoding RNAs (lncRNAs, miRNAs) relevant to kidney diseases.

Conclusions:

• CRISPR-Cas technology represents a significant advancement with transformative potential for kidney disease management.
• Personalized and precise therapeutic strategies targeting genetic mechanisms can improve patient outcomes.
• Challenges in delivery efficiency and off-target effects require further research and development.